presents

Castrol proudly presents: Drive Me To The Moon

Castrol unveils a new documentary in collaboration with Lunar Outpost: a worldwide premiere at Space Center Houston LONDON, Jan. 15,…

1 week ago

ASUS Republic of Gamers Presents Next-Gen Gaming Innovations, Commemorates 20 Years of Gaming Excellence at CES 2026

KEY POINTS Two decades of gaming leadership: At its Dare to Innovate virtual event, ROG celebrates 20 years of fearless…

3 weeks ago

Samsung Presents ‘Your Companion to AI Living’ at The First Look during CES 2026

Next-generation AI-powered devices and experiences to be showcased at the company's exclusive exhibition through January 7LAS VEGAS, Jan. 5, 2026…

3 weeks ago

Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as…

2 months ago

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…

2 months ago

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…

2 months ago

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…

2 months ago

ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025 20:00 ET  | Source: ORIC Pharmaceuticals Highly differentiated 1L preliminary systemic activity of 67% ORR and 100%…

2 months ago

ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025 01:00 ET  | Source: ORIC Pharmaceuticals Systemic activity of 35% ORR in 2L+ patients, including in patients…

2 months ago

Clarivate Presents Cortellis Regulatory AI Assistant to Cut Through Complexity in Safety and Compliance

Powered by agentic AI, new features help regulatory teams improve accuracy and enable faster, more confident decisions across the product…

2 months ago